Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-30
- Development stage
- Preclinical
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intraperitoneal
01
Overview
Recombinant interleukin-30 (rIL30) is a cytokine therapy based on the p28 subunit of interleukin-27. Although p28 typically functions as part of the IL-27 heterodimer, IL-30 can act independently to regulate immune responses. It serves as a natural antagonist of gp130-mediated signaling, which is a shared receptor subunit for the IL-6 family of cytokines. By blocking gp130, IL-30 inhibits the pro-inflammatory signaling of IL-6 and IL-27, affecting the polarization of T helper 1 (Th1) and T helper 17 (Th17) cells. Preclinical research indicates that rIL30 can protect against sepsis-induced mortality by promoting IL-10 production in natural killer T (NKT) cells and reducing systemic inflammation. It also shows potential in treating autoimmune skin conditions like psoriasis by suppressing dendritic cell maturation and keratinocyte cytokine production.
- Other names
- rIL30rIL-30rIL 30IL-30IL30IL 30recombinant IL-30IL-27p28IL27p28IL 27p28p28 subunit of IL-27p-28 subunit of IL-27p 28 subunit of IL-27
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)IL27RA (Interleukin-27 receptor subunit alpha)IL6ST (Interleukin-6 receptor subunit beta)
Beyond the preview
Go deeper on interleukin-30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-30.